Helix BioPharma Total Debt vs. Shares Owned By Insiders

HBP Stock  CAD 0.87  0.07  7.45%   
Based on the key profitability measurements obtained from Helix BioPharma's financial statements, Helix BioPharma's profitability may be sliding down. It has an above-average odds of reporting lower numbers next quarter. Profitability indicators assess Helix BioPharma's ability to earn profits and add value for shareholders. At this time, Helix BioPharma's Price To Sales Ratio is very stable compared to the past year. As of the 12th of December 2024, Days Sales Outstanding is likely to grow to 74.71, while Operating Cash Flow Sales Ratio is likely to drop (4.00). At this time, Helix BioPharma's Interest Income is very stable compared to the past year. As of the 12th of December 2024, Net Interest Income is likely to grow to about 25.2 K, while Accumulated Other Comprehensive Income is likely to drop about 2.8 M.
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.690.68
Fairly Up
Slightly volatile
For Helix BioPharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Helix BioPharma to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Helix BioPharma Corp utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Helix BioPharma's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Helix BioPharma Corp over time as well as its relative position and ranking within its peers.
  
Check out Risk vs Return Analysis.
Please note, there is a significant difference between Helix BioPharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Helix BioPharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Helix BioPharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Helix BioPharma Corp Shares Owned By Insiders vs. Total Debt Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Helix BioPharma's current stock value. Our valuation model uses many indicators to compare Helix BioPharma value to that of its competitors to determine the firm's financial worth.
Helix BioPharma Corp is rated # 5 in total debt category among its peers. It also is rated # 5 in shares owned by insiders category among its peers . The ratio of Total Debt to Shares Owned By Insiders for Helix BioPharma Corp is about  734,419 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Helix BioPharma by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Helix BioPharma's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.

Helix Total Debt vs. Competition

Helix BioPharma Corp is rated # 5 in total debt category among its peers. Total debt of Health Care industry is currently estimated at about 82.88 Million. Helix BioPharma claims roughly 1.58 Million in total debt contributing just under 2% to equities under Health Care industry.
Total debt  Revenue  Valuation  Capitalization  Workforce

Helix Shares Owned By Insiders vs. Total Debt

Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.

Helix BioPharma

Total Debt

 = 

Bonds

+

Notes

 = 
1.58 M
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.

Helix BioPharma

Insiders Shares

 = 

Executives Shares

+

Employees

 = 
2.15 %
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.

Helix Shares Owned By Insiders Comparison

Helix BioPharma is currently under evaluation in shares owned by insiders category among its peers.

Helix BioPharma Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Helix BioPharma, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Helix BioPharma will eventually generate negative long term returns. The profitability progress is the general direction of Helix BioPharma's change in net profit over the period of time. It can combine multiple indicators of Helix BioPharma, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive IncomeM2.8 M
Operating Income-9.4 M-9.8 M
Income Before Tax-9.4 M-9.9 M
Total Other Income Expense Net-25 K-26.2 K
Net Loss-9.3 M-9.7 M
Income Tax Expense-132 K-138.6 K
Net Loss-9.3 M-9.7 M
Net Loss-7.2 M-7.6 M
Interest Income35.6 K37 K
Net Interest Income24 K25.2 K
Change To Netincome840.6 K882.6 K
Net Loss(0.21)(0.22)
Income Quality 0.56  0.73 
Net Income Per E B T 1.13  1.03 

Helix Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Helix BioPharma. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Helix BioPharma position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Helix BioPharma's important profitability drivers and their relationship over time.

Use Helix BioPharma in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Helix BioPharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Helix BioPharma will appreciate offsetting losses from the drop in the long position's value.

Helix BioPharma Pair Trading

Helix BioPharma Corp Pair Trading Analysis

The ability to find closely correlated positions to Helix BioPharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Helix BioPharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Helix BioPharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Helix BioPharma Corp to buy it.
The correlation of Helix BioPharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Helix BioPharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Helix BioPharma Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Helix BioPharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Helix BioPharma position

In addition to having Helix BioPharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Oil And Gas Thematic Idea Now

Oil And Gas
Oil And Gas Theme
Companies involved in drilling, production, and distribution of oil and gas pipelines. The Oil And Gas theme has 37 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Oil And Gas Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in Helix Stock

To fully project Helix BioPharma's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Helix BioPharma Corp at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Helix BioPharma's income statement, its balance sheet, and the statement of cash flows.
Potential Helix BioPharma investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Helix BioPharma investors may work on each financial statement separately, they are all related. The changes in Helix BioPharma's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Helix BioPharma's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.